Fiche du document
2015
- doi: 10.1016/j.cell.2015.08.031
- issn: 0092-8674
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cell.2015.08.031
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26359988
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1097-4172
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_315D44A92CD88
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
CachexyCiter ce document
A.J. Johnston et al., « Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. », Serveur académique Lausannois, ID : 10.1016/j.cell.2015.08.031
Métriques
Partage / Export
Résumé
The cytokine TWEAK and its cognate receptor Fn14 are members of the TNF/TNFR superfamily and are upregulated in tumors. We found that Fn14, when expressed in tumors, causes cachexia and that antibodies against Fn14 dramatically extended lifespan by inhibiting tumor-induced weight loss although having only moderate inhibitory effects on tumor growth. Anti-Fn14 antibodies prevented tumor-induced inflammation and loss of fat and muscle mass. Fn14 signaling in the tumor, rather than host, is responsible for inducing this cachexia because tumors in Fn14- and TWEAK-deficient hosts developed cachexia that was comparable to that of wild-type mice. These results extend the role of Fn14 in wound repair and muscle development to involvement in the etiology of cachexia and indicate that Fn14 antibodies may be a promising approach to treat cachexia, thereby extending lifespan and improving quality of life for cancer patients.